• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Funding Roundup

Pear Therapeutics closes $80M Series D

December 9, 2020 By Sean Whooley

Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Novartis, opioids, peartherapeutics

Brooklyn spending $500K on BioBAT research and manufacturing space

November 17, 2020 By Sean Whooley

SUNY Downstate Health Sciences University announced that it received a $500,000 capital fund grant from Brooklyn to construct a research space. Brooklyn Borough President Eric Adams awarded the grant to SUNY to construct a state-of-the-art biotechnology research and manufacturing space at BioBAT, a nonprofit organization seeking to grow the biotechnology industry in New York City. […]

Filed Under: Business/Financial News, Discovery, Drug-Device Combinations, Featured, Funding Roundup Tagged With: BioBAT, SUNY Downstate

Baxter lands major DoD contract

November 13, 2020 By Sean Whooley

Baxter

The U.S. Defense Dept. (DoD) announced that it awarded Baxter (NYSE:BAX) $40 million for its infusion pumps and accessories. Baxter’s contract includes a maximum $40 million fixed-price award with economic-price-adjustment and indefinite-delivery/indefinite-quantity for its infusion pumps and accessories. The competitive acquisition had 105 offers received. The five-year contract has no option periods with the location being […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Baxter, U.S. Defense Dept.

HHS gives Vaxxas $22M to support vaccine patch tech

October 5, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup Tagged With: BARDA, coronavirus, COVID-19, HHS, Merck, Vaxxas

Enable Injections completes $25M credit facility

September 8, 2020 By Sean Whooley

enfuse-enable-injections

Enable Injections announced today that it completed a credit facility worth $25 million from Oxford Finance LLC. Cincinnati-based Enable Injections said in a news release that the funds are earmarked for supporting the scaling of high-volume manufacturing and the achievement of major inflection points as it moves toward commercialization. The company develops the enFuse, a […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Enable Injections

CureVac stock soars after $213.3M IPO

August 17, 2020 By Sean Whooley

Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: coronavirus, COVID-19, CureVac

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

July 24, 2020 By Sean Whooley

Inovio Pharma

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, U.S. Defense Dept.

Smiths Medical lands major vaccine-related contract

July 15, 2020 By Nancy Crotti

Smiths Medical announced today that it has landed a federal contract to produce more than 78 million syringe-and-needle units and $20 million in federal funding to expand its Keene, N.H. plant to produce them. The Plymouth, Minn.-based company said it received an order for 78.6 million syringe-and-needle units and that BARDA and the Joint Program […]

Filed Under: Business/Financial News, Contract Services, Featured, Funding Roundup Tagged With: BARDA, coronavirus, COVID-19

Bigfoot Biomedical raises $55m in Series C

June 3, 2020 By Sean Whooley

Bigfoot Biomedical updated logo

Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management. Get the full story at our sister site, MassDevice.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Funding Roundup, Patient Monitoring Tagged With: abbott, Bigfoot Biomedical

Ocular Therapeutix commences public offering

May 20, 2020 By Sean Whooley

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) announced that it commenced an underwritten public offering of an undisclosed amount of its common stock. The Bedford, Mass.-based eye condition therapy developer filed with the SEC to confirm the offering with the shares at a par value of $0.0001 per share. The common stock at market close on May 18 prior to the announcement […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 30
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS